<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03237455</url>
  </required_header>
  <id_info>
    <org_study_id>0102-17-EMC</org_study_id>
    <nct_id>NCT03237455</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging in High Risk Patients for the Development of Diffuse Idiopathic Skeletal Hyperostosis (DISH)</brief_title>
  <official_title>Magnetic Resonance Imaging in High Risk Patients for the Development of Diffuse Idiopathic Skeletal Hyperostosis (DISH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Chaim Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diffuse idiopathic skeletal hyperostosis (DISH) is a poorly understood, systemic condition
      characterized by progressive calcification and ossification of ligaments and entheses. The
      current classification criteria allow diagnosing the disease in its late course, when
      significant bony overgrowth already involves the vertebral column and the appendicular
      skeleton. The research of the pathogenic mechanisms in DISH, is significantly hampered by the
      late diagnosis resulting from this definition.Based on recent MRI studies in both axial
      spondyloarthritis (axSpA) and in DISH, it seems that changes similar to the classical early
      inflammatory changes described in axSpA, can be detected in patients with DISH. We therefore
      hypothesize, that patients with metabolic syndrome without radiographic evidence for spinal
      DISH, might exhibit early MRI changes. If this hypothesis proves to be correct, early
      diagnosis and research of the possible pathogenetic mechanisms at this early stage might be
      very rewarding in investigations of the early aberrations of the entheses homeostasis and
      eventually early, more targeted therapeutic interventions. The study will examine MRI changes
      in patients, in their 5th decade of life, with high risk for the development of DISH (ie
      diabetes mellitus, metabolic syndrome) compared with patients who don't have this risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient's selection- Patients will be recruited from obesity/metabolic/diabetes clinics and
      from bariatric surgeries clinics. All patients will have the diagnosis of metabolic syndrome
      National Cholesterol Education Panel III (NCEP). Patients in their 5th decade of life will be
      recruited for the study. This study group will have to meet the NCEP 3 criteria for metabolic
      syndrome and/or have type 2 diabetes mellitus (9). An age and sex matched individuals who do
      not meet these pre-requisits will serve as a control group.

      All asymptomatic patients will undergo postero-anterior and lateral x-rays of the thoracic
      spine, unless they have postero-anterior or lateral thoracic spine or chest x-rays in the
      year preceding the recruitment. For patients with back pain, addition of cervical or lumbar
      spine radiographs will be permitted based on the physician judgement. Patients recruited for
      the study will have a total spine and sacroiliac MRI (see below) read by radiologists and
      rheumatologists, expert in musculoskeletal imaging, who will be blinded for the patient's
      data. The readings of the radiographs and the MRI will be performed in a random order.

      All patients and controls will undergo postero anterior and lateral thoracic spine X-rays and
      MRI of the entire spine and their sacroiliac joints (Spine: sagittal T1-weighted and T2 with
      fat suppression sequences, SIJ semicoronal T1-weighted and T2 with fat suppression sequences)
      at study entry.

      An accepted scoring system for the interpretation of the MRI studies will be employed for
      both the spine and the sacroiliac joints.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>case control study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Reader of the MRI studies will be blinded to the patients diagnoses</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory changes in the spine and/or sacroiliac joints</measure>
    <time_frame>6 months</time_frame>
    <description>inflammatory bone marrow edema lesions and fatty lesions and the anterior and posterior corners of the spine (Berlin score) as well as for the presence of enthesitis on the posterior elements.
The sacroiliac joints will also be scored according to the Berlin scoring method for the presence of acute and structural inflammatory lesion, including BME, fat metaplasia, erosions, sclerosis, ankylosis. Anterior and posterior extraarticular enthesitis will also be registered</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperostosis, Diffuse Idiopathic Skeletal</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Thoracic spine x-rays+whole spine MRI</intervention_name>
    <description>PA radiographs of the thoracic spine and MRI of the whole spine and sacroiliac joints</description>
    <arm_group_label>study group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood tests</intervention_name>
    <description>blood chemistry including total cholesterol, LDL HDL, CBC, HbA1C, fasting glucose, TG, and insulin levels, HLA-B27, 2 vials of frozen serum for future studies.</description>
    <arm_group_label>study group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>laboratory</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>constitutional and demographic data collection</intervention_name>
    <description>demographics, concomitant diseases (in particular type 2 DM, hypertension, hyperlipidemia) concomitant medications, height and weight (BMI), waist circumference</description>
    <arm_group_label>study group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>data</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet the NCEP 3 criteria for metabolic syndrome and/or have type 2 diabetes mellitus
             (9).

        Age 40-49 years

        Exclusion Criteria:

          -  ESR and CRP levels above common levels adjusted for age, gender, and weight.(I have
             ref for the determination of common CRP levels).

        Positive HLA B-27 Personal or family history of Spondyloarthritis, psoriasis or
        inflammatory arthritis (past or present) Inflammatory back pain as defined by the ASAS
        definition (age at onset &lt;40y, insidious onset, improvement with exercise, no improvement
        with rest, pain at night with improvement upon getting up = IBP if 4/5 items are present)
        (Ref) History of uveitis Plain radiographs with evidence for DISH
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reuven Mader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HaEmek MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reuven Mader, MD</last_name>
    <phone>972-4-6494354</phone>
    <email>mader_r@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irina Novofastovski, MD</last_name>
    <phone>972-4-6494354</phone>
    <email>irina_no@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HaEmek MC and Chaim Sheba MC</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reuven Mader, MD</last_name>
      <phone>972-4-6494354</phone>
      <email>mader_r@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Irina Novofastovski, MD</last_name>
      <phone>972-4-6494354</phone>
      <email>Irina_no@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Irina Novofastovski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdallah Fawaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir Bieber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iris Eshed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reuven Mader, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Mader R, Verlaan JJ, Buskila D. Diffuse idiopathic skeletal hyperostosis: clinical features and pathogenic mechanisms. Nat Rev Rheumatol. 2013 Dec;9(12):741-50. doi: 10.1038/nrrheum.2013.165. Epub 2013 Nov 5. Review.</citation>
    <PMID>24189840</PMID>
  </reference>
  <reference>
    <citation>Mader R, Novofestovski I, Adawi M, Lavi I. Metabolic syndrome and cardiovascular risk in patients with diffuse idiopathic skeletal hyperostosis. Semin Arthritis Rheum. 2009 Apr;38(5):361-5. doi: 10.1016/j.semarthrit.2008.01.010. Epub 2008 Mar 4.</citation>
    <PMID>18304611</PMID>
  </reference>
  <reference>
    <citation>Mader R, Buskila D, Verlaan JJ, Atzeni F, Olivieri I, Pappone N, Di Girolamo C, Sarzi-Puttini P. Developing new classification criteria for diffuse idiopathic skeletal hyperostosis: back to square one. Rheumatology (Oxford). 2013 Feb;52(2):326-30. doi: 10.1093/rheumatology/kes257. Epub 2012 Sep 29.</citation>
    <PMID>23024057</PMID>
  </reference>
  <reference>
    <citation>Weiss BG, Bachmann LM, Pfirrmann CW, Kissling RO, Zubler V. Whole Body Magnetic Resonance Imaging Features in Diffuse Idiopathic Skeletal Hyperostosis in Conjunction with Clinical Variables to Whole Body MRI and Clinical Variables in Ankylosing Spondylitis. J Rheumatol. 2016 Feb;43(2):335-42. doi: 10.3899/jrheum.150162. Epub 2015 Dec 15.</citation>
    <PMID>26669910</PMID>
  </reference>
  <reference>
    <citation>Mader R, Novofastovski I, Iervolino S, Pavlov A, Chervinsky L, Schwartz N, Pappone N. Ultrasonography of peripheral entheses in the diagnosis and understanding of diffuse idiopathic skeletal hyperostosis (DISH). Rheumatol Int. 2015 Mar;35(3):493-7. doi: 10.1007/s00296-014-3190-0. Epub 2014 Dec 13.</citation>
    <PMID>25503650</PMID>
  </reference>
  <reference>
    <citation>Arad U, Elkayam O, Eshed I. Magnetic resonance imaging in diffuse idiopathic skeletal hyperostosis: similarities to axial spondyloarthritis. Clin Rheumatol. 2017 Jul;36(7):1545-1549. doi: 10.1007/s10067-017-3617-6. Epub 2017 Mar 31.</citation>
    <PMID>28364275</PMID>
  </reference>
  <reference>
    <citation>Julkunen H, Heinonen OP, Pyörälä K. Hyperostosis of the spine in an adult population. Its relation to hyperglycaemia and obesity. Ann Rheum Dis. 1971 Nov;30(6):605-12.</citation>
    <PMID>5130140</PMID>
  </reference>
  <reference>
    <citation>8. Mader R, Fawaz A, Bieber A, Novofastovski I. Diffuse idiopathic skeletal hyperostosis (DISH) of young adults: lessons to be learnt. Austin J Orthopade &amp; Rheumatol. 2016; 3(4): 1043.</citation>
  </reference>
  <reference>
    <citation>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97.</citation>
    <PMID>11368702</PMID>
  </reference>
  <reference>
    <citation>Landewé RB, Hermann KG, van der Heijde DM, Baraliakos X, Jurik AG, Lambert RG, Østergaard M, Rudwaleit M, Salonen DC, Braun J. Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. J Rheumatol. 2005 Oct;32(10):2050-5.</citation>
    <PMID>16206369</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>HaEmek Medical Center, Israel</investigator_affiliation>
    <investigator_full_name>Reuven Mader</investigator_full_name>
    <investigator_title>Associate clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hyperostosis</mesh_term>
    <mesh_term>Hyperostosis, Diffuse Idiopathic Skeletal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Other researchers are expected to perform the study in their own countries. If they perform the study, unidentified data from the present study will be processed with the other parties data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

